ReviewJournal of thoracic disease2014
Molecular markers to predict clinical outcome and radiation induced toxicity in lung cancer.
Review in Journal of thoracic disease, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 2 syntheses or guidelines pooled it, 26 citations in OpenAlex.
- Skin CanceR Brachytherapy vs External beam radiation therapy (SCRiBE) meta-analysis.Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology · 2018Pooled it
- Hypofractionated radiation therapy for basal and squamous cell skin cancer: A meta-analysis.Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology · 2017Pooled it
- Electron Irradiation Effects on N and FeInternational journal of nanomedicine · 2026Article
- Analysis of second-line therapy in patients with prior pneumonitis receiving first-line combination immunotherapy for advanced non-small cell lung cancer.Translational lung cancer research · 2025Article
- Resistance to Radiotherapy in Cancer.Diseases (Basel, Switzerland) · 2025Review
- Two germline mutations can serve as genetic susceptibility screening makers for a lung adenocarcinoma family.Journal of cancer research and clinical oncology · 2023Article
- PPDPF Promotes the Progression and acts as an Antiapoptotic Protein in Non-Small Cell Lung Cancer.International journal of biological sciences · 2022Article
- Artificial Intelligence Applications to Improve the Treatment of Locally Advanced Non-Small Cell Lung Cancers.Cancers · 2021Review
- Monitoring DNA Damage and Repair in Peripheral Blood Mononuclear Cells of Lung Cancer Radiotherapy Patients.Cancers · 2020Article
- Markers Useful in Monitoring Radiation-Induced Lung Injury in Lung Cancer Patients: A Review.Journal of personalized medicine · 2020Review
- AOncoimmunology · 2020Article
- Diabetes mellitus is a predictive factor for radiation pneumonitis after thoracic radiotherapy in patients with lung cancer.Cancer management and research · 2019Article
- Genetic variants in the plasminogen activator inhibitor-1 gene are associated with an increased risk of radiation pneumonitis in lung cancer patients.Cancer medicine · 2017Article
- Genetic variants in PI3K/AKT pathway are associated with severe radiation pneumonitis in lung cancer patients treated with radiation therapy.Cancer medicine · 2016Article
- Sequencing study on familial lung squamous cancer.Oncology letters · 2015Article
- Stereotactic body radiotherapy for Stage I lung cancer with chronic obstructive pulmonary disease: special reference to survival and radiation-induced pneumonitis.Journal of radiation research · 2015Article
- The role of SOX-2 on the survival of patients with non-small cell lung cancer.Journal of thoracic disease · 2015Article
- Interleukin polymorphisms associated with overall survival, disease-free survival, and recurrence in non-small cell lung cancer patients.Molecular carcinogenesis · 2015Article
- Article
- Analysis of chromosome 17 miRNAs and their importance in medulloblastomas.BioMed research international · 2015Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
Abstract
The elucidation of driver mutations involved in the molecular pathogenesis of cancer has led to a surge in the application of novel targeted therapeutics in lung cancer. Novel oncologic research continues to lead investigators towards targeting personalized tumor characteristics rather than applying targeted therapy to broad patient populations. Several driver genes, in particular epidermal growth factor receptor (EGFR) and ALK fusions, are the earliest to have made their way into clinical trials. The avant-garde role of genomic profiling has led to important clinical challenges when adapting current standard treatments to personalized oncologic care. This new frontier of medicine requires newer biomarkers for toxicity that will identify patients at risk, as well as, new molecular markers to predict and assess clinical outcomes. Thus far, several signature genes have been developed to predict outcome as well as genetic factors related to inflammation to predict toxicity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.